|
Nanogen shares surge on FDA progress w/ plasma test -
Nanogen shares jumped 24.4% to $3.36 in pre-market action on Wednesday after the company received 510(k) clearance to market its StatusFirst CHF NT-proBNP EDTA plasma test as an aid to the diagnosis of congestive heart failure from the Food and Drug Administration. The issue was the second most active stock on Instinet with volume reaching 266,623. The San Diego-based company plans to continue development work on its StatusFirst CHF whole blood test.
Quelle: StockMarket
Last 3.39$ +25%
__________________
liebe Grüße von Coco
|